UNION STRONG Completes Nearly RMB 100 Million Series D Financing to Accelerate Industrialization of Intelligent Cerebrovascular Disease Diagnosis and Treatment Solutions

VCBeat has exclusively learned that, recently,Union Strong (Beijing) Tech. Co., Ltd. (hereinafter referred to as “Union Strong”)^®”）Completed nearly RMB 100 million in Series D financing, with this round led byYantai Biomedical Health Industry Development Master Fund (hereinafter referred to as the "Yantai Biomedical Master Fund")Direct investment, this significant strategic investment will benefit Union Strong^®...injecting strong momentum into its future development. Meanwhile, with the strong support of Yantai Guofeng Investment Holding Group and Yantai Biomedical Health Industry Development Group, Union Strong^®Signed on to settle in the Blue Medicine Valley · Life Island Industrial Park, a key life and health industrial park developed by Yantai City.

The Yantai Biomedical Master Fund was established in August 2021 with a scale of RMB 10 billion. Initiated by Yantai Guofeng Investment Holding Group Co., Ltd., the fund has introduced state-owned capital from the provincial, municipal, and district levels, as well as select leading enterprises in Yantai’s biomedical industry chain, as strategic investors. The fund’s primary investment areas include innovative drugs, high-end active pharmaceutical ingredients (APIs), rehabilitation aids and high-end medical devices, traditional Chinese medicine (TCM), foods for special medical purposes (FSMP) and health supplements, healthcare big data, medical aesthetics products, and cell and gene therapy. As the lead investor and strategic investor in this round of financing, the Yantai Biomedical Master Fund has invested in Union Strong^®has given high recognition to its development prospects.

The fund's investments will be primarily used to support Union Strong.^®In the fields of industrialization, R&D innovation, and market expansion for intelligent diagnosis and treatment of cerebrovascular diseases, Union Strong is poised to achieve greater breakthroughs and development through its collaboration with the Yantai Biomedical Health Industry Development Master Fund Partnership (Limited Partnership).^®There will be more opportunities to engage in in-depth collaborations with leading enterprises and institutions in the industry, jointly driving innovation and development in China’s biopharmaceutical and health sector.

On the morning of December 20, the Conference on Capital Empowering the High-Quality Development of the Biomedical Industry Chain was grandly held in Yantai. The event was jointly hosted by the Office of the “Chain Chief” System for Yantai’s Biomedical Industry Chain, the People’s Government of Muping District, and Yantai Guofeng Investment Holding Group Co., Ltd., and organized by the Muping District Biomedical Special Task Force, Yantai Biomedical Health Industry Development Group Co., Ltd., and Yantai Tongju Private Equity (Investment) Fund Management Co., Ltd. Zheng Deyan, Deputy Secretary of the Municipal Party Committee and Mayor, attended the conference and delivered a speech. Shen Jian, Member of the Standing Committee of the Municipal Party Committee and Vice Mayor, presided over the meeting. The conference focused on industrial development and investment and financing trends, aiming to promote the aggregation of resources and innovative development in the biomedical industry.

At the meeting, the Biomedical Group and Union Strong^®Seventeen domestic and international enterprises, including Union Strong, have signed agreements to establish projects in the zone and park, collectively settling into Yantai’s flagship life and health industrial hub—Blue Medicine Valley · Life Island. This move will further promote resource sharing, complementary advantages, and win-win cooperation among all parties.^®As one of the contracted enterprises, Union Strong® boasts leading technology and extensive experience in the field of intelligent diagnosis and treatment of cerebrovascular diseases. Driven by technological innovation, the company is committed to providing more efficient and precise integrated solutions for the intelligent diagnosis and treatment of cerebrovascular diseases to patients worldwide. Through close collaboration with Yantai Biomedical Group, Union Strong® will further promote the innovative development and globalization of China's biomedical and health industry.

Union Strong^®Qin Lan, Founder and Chairmanstated: “In 2023, the biopharmaceutical industry experienced significant market adjustments and changes. As the sector underwent deep restructuring and optimization, institutional investors shifted their investment stance toward biopharmaceuticals, placing greater emphasis on companies’ technological barriers, product leadership, and commercialization capabilities. They adopted a more cautious approach in selecting investment targets to achieve high returns while mitigating investment risks. The success of this financing round is not only a testament to Union Strong^®affirmation of the technological leadership and business model certainty of our products, but also recognition of our corporate mission, vision, and team values. I am well aware that behind every success lies the relentless efforts of our team and the strong support of our partners. In this process, we have established deep connections with Yantai, a renowned city for advanced manufacturing and a modern international coastal city in the new era, which has also provided Union Strong^®...injecting new momentum into its future development. Seizing this financing opportunity, we will continue to deepen our expertise in the intelligent diagnosis and treatment of cerebrovascular diseases, providing global patients with safer and more precise comprehensive solutions. Meanwhile, we look forward to collaborating with more partners to drive industry innovation and development, harnessing the power of technology to safeguard lives.”

Industrial Investor: Yantai Biomedical Master Fundstated: "Union Strong^®The team possesses the core elements and capabilities to build a world-leading innovative biopharmaceutical enterprise in the field of intelligent diagnosis and treatment of cerebrovascular diseases. We, at Union Strong^®“We are confident in the future development and industrial cooperation between both parties, and will fully support the company’s industrial upgrading and growth by providing substantial assistance in areas such as resources and financing. This support aims to help the company become a global leader in medical artificial intelligence and an important engine for the high-quality development of Yantai’s biomedical industry.”

Although investment in the biopharmaceutical industry shrank in 2023, Union Strong^®With its superior technological capabilities and strong commercial prospects, it has still garnered favor from numerous institutional investors. This fully demonstrates Union Strong^®Competitiveness and Development Potential in the Biopharmaceutical Industry. 2023 was a year of significant progress for Union Strong®. The company achieved important breakthroughs and results in product research and development, market expansion, and cooperative exchanges, earning multiple national-level certifications and honors, such as being designated as a National “Little Giant” Enterprise Specialized in Refinement, Uniqueness, and Innovation, and a National Intellectual Property Advantage Unit. These accolades fully demonstrate the company’s leading position and strong innovative capabilities in the field of intelligent diagnosis and treatment.

In terms of product R&D, UKnow, the first Class III innovative medical device certified for “AI + Therapy” in China^®The “Intracranial Aneurysm Surgical Planning Software” has achieved another breakthrough. This product has passed the national scientific and technological achievement appraisal, been rated at the highest level of “internationally leading,” and been included in the Catalogue of Major Technical Equipment (First Set) in Beijing, opening a new chapter for the company’s product promotion and market expansion. Based on the continuous optimization and upgrading of software algorithms, the supporting “UMate™ Self-Service Shaping Terminal” has achieved small-scale mass production, as Union Strong^®As a key component of the integrated AI surgical solution, it has continuously gained clinical validation and recognition at national centers for neurological diseases, including Xuanwu Hospital of Capital Medical University and Huashan Hospital Affiliated to Fudan University, as well as at key provincial and municipal hospitals across the country. The company’s other core product, “UKnow^®“Risk Intracranial Aneurysm Auxiliary Assessment Software” was approved in May this year to enter the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. As China’s first innovative medical device featuring “AI + Decision-Making,” this software provides clinicians with more precise treatment decision support. The prospective, multicenter, randomized controlled trial for this product has been successfully completed, fully validating its safety and efficacy.

On the path toward future industrialization, Union Strong^®Union Strong will continue to uphold its mission of “Empowering Healthcare with AI, Safeguarding Lives with Technology,” and steadfastly advance the research, development, and application of intelligent diagnostic and therapeutic technologies for cerebrovascular diseases. The company will further increase its R&D investment, focusing on core pain points in treatment and leveraging its three-dimensional business model of “Product + Service” to build a more diversified product portfolio. It aims to continuously enhance product performance, expand coverage across multiple cerebrovascular conditions, and facilitate the upgrade and iteration from traditional surgical procedures to AI-enabled ones. By integrating intelligent software with automated diagnostic and therapeutic equipment, Union Strong^®A solution enabling “fully autonomous driving” of critical surgical steps will be realized. This innovative technological transformation will shift neurointerventional surgery from traditional manual operation to an AI-driven, human-machine collaborative treatment model, ushering the entire healthcare sector into a new stage of development.

For primary care physicians and young doctors, this novel AI-driven treatment approach will significantly shorten their learning curve. By leveraging Union Strong^®The “fully autonomous” AI-driven therapeutic solution enables rapid mastery of critical surgical steps, enhancing surgical skills and treatment outcomes through human-machine collaboration. This will help genuinely narrow the gap in medical care standards between urban and rural areas, empowering more primary-care and young physicians to provide patients with more efficient and timely treatment. On a broader scale, the application of intelligent diagnosis and treatment for cerebrovascular diseases holds promise for truly achieving the national strategic goal of “managing serious illnesses within county-level jurisdictions.” This means that even primary healthcare institutions below the county level can deliver high-quality diagnostic and therapeutic services to patients using such advanced technologies. This will significantly improve the accessibility and equity of healthcare services, allowing more patients to enjoy high-quality medical care close to home, thereby providing them with better diagnostic and treatment experiences and an improved quality of life.

Union Strong^®’s mission is not merely to provide advanced technologies and products, but also to embody reverence for and care for life. As a company with a grand vision, Union Strong^®The goal is to become the world’s leading intelligent diagnosis and treatment service platform for stroke. This means not only leading industry development in terms of originality, uniqueness, and technological barriers of technologies and products, but also becoming an industry leader in services, brand influence, and market share.

Union Strong^®We aim to forge closer ties with Yantai’s biomedical industry chain through our own efforts. Seizing the opportunities presented by the high-quality development of Yantai’s biomedical sector, the company will actively expand its market presence, enhance its technological capabilities, and strengthen industry-academia-research collaborations. By leveraging Yantai’s resources and advantages in biomedicine, we will work closely with clinical centers, research institutes, and upstream and downstream enterprises to jointly advance the level of intelligent diagnosis and treatment for cerebrovascular diseases in China and worldwide.

Looking Ahead, Union Strong^®Guided by patient needs and centered on addressing treatment pain points, we will continue to optimize our products and services. With its unique perspective and innovative capabilities, Union Strong is leading the development of intelligent diagnosis and treatment for cerebrovascular diseases globally. We believe that, with the support and collaboration of the government, shareholders, and industry partners, Union Strong^®Bringing greater hope and well-being to patients worldwide.